Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143YN | ISIN: GB00BYX3WZ24 | Ticker-Symbol: 5HU
Frankfurt
22.11.24
21:49 Uhr
0,008 Euro
-0,004
-33,33 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HEMOGENYX PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
HEMOGENYX PHARMACEUTICALS PLC 5-Tage-Chart

Aktuelle News zur HEMOGENYX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln
FrHemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting285Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New Articles of Association LONDON, UK / ACCESSWIRE...
► Artikel lesen
FrHemogenyx Pharma Plc - Notice of Extraordinary General Meeting2
FrHemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial192Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical...
► Artikel lesen
FrHemogenyx Pharma Plc - IRB Approval for Phase I Clinical Trial1
11.11.Hemogenyx Pharmaceuticals PLC Announces Institutional Investment240Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx...
► Artikel lesen
11.11.Hemogenyx Pharma Plc - Institutional Investment1
30.10.IN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trial-
30.10.Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening118Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)...
► Artikel lesen
30.10.Hemogenyx Pharma Plc - Schedule for Phase I Clinical Trial Opening1
02.10.Hemogenyx shares boosted by partner investment6
02.10.Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC303Prevail Partners, LLC to invest again in Hemogenyx PharmaceuticalsPrevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED...
► Artikel lesen
02.10.Hemogenyx Pharma Plc - Strategic Investment from Prevail Partners, LLC1
27.09.Hemogenyx Pharmaceuticals loss narrows amid reduced expenses1
27.09.Hemogenyx Pharmaceuticals PLC Announces Half-year Report145LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose...
► Artikel lesen
27.09.Hemogenyx Pharma Plc - Half-year Report2
09.09.Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson158LONDON, UNITED KINGDOM / ACCESSWIRE / September 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases...
► Artikel lesen
09.09.Hemogenyx Pharma Plc - FLT3 Assay Ready for Phase I Trials at MD Anderson1
02.09.Hemogenyx Pharmaceuticals PLC Announces CDX Development Update271CDX Development Update LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical...
► Artikel lesen
02.09.Hemogenyx Pharma Plc - CDX Development Update1
28.08.Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference174LONDON, UNITED KINGDOM / ACCESSWIRE / August 28, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is...
► Artikel lesen
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1